Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 288 results

Pandemic blues: the global approach to COVID-related IP

US20-01-2022Matthew Howell and Lauren Griffin

While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

Amendments to Chinese Patents Law for the Life Sciences

China09-09-2021Keith Haddaway and Christopher Loh

Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.

Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank

International23-06-2021The C5 Group (American Conference Institute, The Canadian Institute, C5)

Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.

Navigating patent eligibility in digital healthcare

US22-06-2021Linda Thayer, Aaron Capron and Sneha Nyshadham

Patent applicants with digital health inventions need to remember that being useful and novel may not be enough, warn Linda Thayer, Aaron Capron and Sneha Nyshadham of Finnegan, Henderson, Farabow, Garrett & Dunner.

The curious case of Wuhan’s Institute of Virology and remdesivir

China20-04-2021Thomas Moga

Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

EPO’s new examination guidelines: what you need to know

EU06-04-2021Clare Roskell and Samantha Moodie

The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

The uncertain future of antibody claims

US01-04-2021Benjamin Pelletier

Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.

The doctrine of equivalents in the medtech arena

US18-11-2020Christopher Bright and Nathan Smith

The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

A stricter interpretation: the EPO and antibodies

EU27-10-2020Joachim Wachenfeld and Florian Grasser

Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.

COVID-19: Protection of IP for AI tools

International, Singapore01-09-2020Mao Xiao Hong and Danny Yap

As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.

Showing 1 to 10 of 288 results